Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Picosulfate→

Picosulfate Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
10040-34-3
Molecular formula
C18H15NO8S2
Molecular weight
437.4 g/mol
Drug class
Stimulant laxativediphenylmethane derivative activated in the colon
Mechanism of action
Sodium picosulfate is converted by colonic bacteria to the active diphenol metabolite, which stimulates colonic mucosa and enteric nerve plexuses, increasing peristalsis and reducing water absorption. Sodium is a counter-ion, not a separate therapeutic target.
Indications / reported uses
  • Short-term relief of constipation
  • Bowel cleansing before diagnostic or surgical procedures when used in an authorised fixed combination (for example, with magnesium citrate); bowel-preparation indications belong to the specific combination regimen

Sources: UK SmPC — Sodium picosulfate oral preparations · NHS — Picosulfate laxative information · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Stimulant laxative; diphenylmethane derivative activated in the colon

Mechanism of action

Sodium picosulfate is converted by colonic bacteria to the active diphenol metabolite, which stimulates colonic mucosa and enteric nerve plexuses, increasing peristalsis and reducing water absorption. Sodium is a counter-ion, not a separate therapeutic target.

General use cases

  • Short-term relief of constipation
  • Bowel cleansing before diagnostic or surgical procedures when used in an authorised fixed combination (for example, with magnesium citrate); bowel-preparation indications belong to the specific combination regimen
Active moiety: picosulfate active moiety (bacterial prodrug) (Simple salt/counter-ion form; shares the same API pharmacology and general use cases.)

The counter-ion does not create a separate therapeutic API. Picosulfate is converted by colonic bacteria to the active diphenol laxative; bowel preparation versus routine constipation use depends on the product combination and regimen.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Picosulfate Environmental Risk Assessment (ERA) (the Picosulfate ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.